Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $22.57.
Several research firms have recently weighed in on ACRV. HC Wainwright boosted their price objective on shares of Acrivon Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. LADENBURG THALM/SH SH cut Acrivon Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, April 29th. JMP Securities lifted their price objective on Acrivon Therapeutics from $14.00 to $17.00 and gave the stock a “market outperform” rating in a report on Thursday, April 25th. BMO Capital Markets reissued an “outperform” rating and issued a $25.00 target price on shares of Acrivon Therapeutics in a report on Wednesday, May 15th. Finally, Piper Sandler boosted their price target on Acrivon Therapeutics from $26.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th.
Get Our Latest Analysis on Acrivon Therapeutics
Institutional Trading of Acrivon Therapeutics
Acrivon Therapeutics Price Performance
Shares of NASDAQ ACRV opened at $7.55 on Monday. The stock has a market cap of $233.14 million, a P/E ratio of -2.62 and a beta of 0.78. Acrivon Therapeutics has a 1 year low of $3.19 and a 1 year high of $12.89. The firm has a 50-day moving average of $7.26 and a 200 day moving average of $6.67.
Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.16. Research analysts expect that Acrivon Therapeutics will post -2.47 earnings per share for the current fiscal year.
About Acrivon Therapeutics
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Recommended Stories
- Five stocks we like better than Acrivon Therapeutics
- Investing in Travel Stocks Benefits
- Should You Invest in Bitcoin? Pros and Cons
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.